This is a medicine used to help people with asthma or COPD breathe easier. It contains two active ingredients: Albuterol and Ipratropium. Albuterol helps relax the muscles around the airways, making it easier to breathe. Ipratropium also helps open up the airways. It's often taken when symptoms flare up, like during an asthma attack.
Every report comes from a Lived member, sent anonymously.
Have you tried Combivent (Albuterol-Ipratropium) for Asthma?
Albuterol-ipratropium is a prescription inhaled medicine that combines two bronchodilators, drugs that open narrowed airways. It is sold as the Combivent Respimat inhaler and as a generic liquid for use in a nebulizer, a machine that turns medicine into a mist breathed in through a mouthpiece or mask. It is approved for people with chronic obstructive pulmonary disease (COPD), a long-term lung disease that includes emphysema and chronic bronchitis, whose airways still tighten despite a regular bronchodilator and who need a second one. It is not approved in the US for asthma, although hospitals and emergency departments often give the two ingredients together during a severe asthma attack. Both ingredients are short-acting, so this medicine relieves symptoms for a few hours at a time. Current COPD guidelines generally build day-to-day treatment around long-acting inhalers, with short-acting medicines like this one used for symptom relief or flare-ups, or when someone needs a nebulizer.
The airways are wrapped in a thin layer of muscle. In COPD, that muscle can tighten and narrow the airways, which makes breathing harder and causes wheezing and chest tightness. Two different signals help keep it tight, and each ingredient blocks one of them. Ipratropium is an anticholinergic. It blocks acetylcholine, a chemical messenger released by nerves in the lungs that tells the airway muscle to contract. Albuterol is a beta2-agonist. It stimulates receptors on the airway muscle that tell it to relax. Because they work by separate routes, the two together can open the airways more than ipratropium alone. In studies, airways typically began opening about 13 minutes after a dose, and the effect lasts around 4 to 5 hours.
Combivent Respimat is a soft-mist inhaler: it releases a slow-moving cloud rather than a fast puff. The usual dose is one inhalation four times a day. A prescriber may allow extra inhalations when symptoms flare, but the total should not go above six in 24 hours. Each cartridge holds 120 inhalations, about a month at four a day, and a dose indicator shows when it is running low. Before first use, the cartridge is pushed into the inhaler and the inhaler is primed: sprayed toward the ground until a cloud appears, then three more times. If it has not been used for more than 3 days, spray once toward the ground first; after more than 21 days, prime it fully again. The inhaler works only with Combivent cartridges. The nebulizer form comes in 3 mL single-dose vials. The usual dose is one vial four times a day, with up to two extra vials a day if needed. Ask the prescriber or pharmacist to watch your technique with either device, and do not raise the dose or frequency on your own.
Many people have few side effects. In the main COPD trial, the most frequent problems were colds and other upper respiratory infections, cough, bronchitis, headache and shortness of breath, which are also common in COPD itself. Less often, people notice a fast or pounding heartbeat, shakiness, nervousness, dizziness, dry mouth, nausea or blurred vision. Dizziness or blurred vision is a reason to be careful with driving until you know how the medicine affects you. Rarely, the medicine tightens the airways instead of opening them, a reaction called paradoxical bronchospasm. If breathing suddenly gets worse or wheezing increases right after a dose, stop using it and call 911. Stop it and get emergency care the same way for signs of a severe allergic reaction, such as swelling of the face, lips, tongue or throat, or hives with trouble breathing. A rash or hives without breathing trouble is also a reason to stop it and call the prescriber. Chest pain or a racing or irregular heartbeat should be reported to the prescriber promptly.
Keep the spray or mist out of your eyes. Ipratropium can raise pressure inside the eye and trigger or worsen narrow-angle glaucoma, a type of glaucoma in which fluid cannot drain from the eye. Eye pain, blurred vision, red eyes, or seeing halos or colored images around lights need a call to the doctor right away. People using a nebulizer with a face mask should make sure it fits well. Ipratropium can also make it harder to empty the bladder, especially for men with an enlarged prostate; difficulty urinating should be reported. The medicine is not for anyone allergic to atropine or similar drugs, or to its ingredients. Albuterol can raise heart rate and blood pressure, so people with heart disease, an irregular heart rhythm, high blood pressure, an overactive thyroid, seizures or diabetes should make sure the prescriber knows before starting, as should anyone who already has narrow-angle glaucoma. Tell the prescriber about every other medicine you take. Using it with other anticholinergic medicines, including the long-acting COPD inhaler tiotropium (Spiriva), can add up their side effects. Beta-blockers, used for blood pressure and heart conditions, can blunt albuterol and may tighten airways. Water pills such as loop or thiazide diuretics can lower potassium, and albuterol can lower it further. Certain older antidepressants, MAO (monoamine oxidase) inhibitors and tricyclics, can intensify albuterol's effects on the heart and blood vessels, even within 2 weeks of stopping them. Anyone pregnant, planning pregnancy or breastfeeding should discuss use with the prescriber; studies have not shown a consistent risk of birth defects from either ingredient.
Relief usually starts within minutes and lasts several hours, so many people notice easier breathing soon after a dose. It does not cure COPD or stop it from progressing. Its job is to ease airway tightening, usually alongside other treatment such as long-acting inhalers, pulmonary rehabilitation and stopping smoking. How often you use it is a useful signal. If the usual dose stops giving the usual relief, symptoms are getting worse, or you need it more often than usual, contact the care team right away rather than taking more puffs. This often means COPD is worsening and treatment needs to be reassessed, and going over the daily limit can be dangerous. At follow-up visits, the care team may review symptoms, flare-ups, inhaler technique and whether a long-acting medicine would control symptoms better.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Combivent (Albuterol-Ipratropium), what you've noticed, or ask the community a question.